Allergan AGN
-
Cramer's Lightning Round - EZchip Semiconductor Is Too Dicey (5/6/13)
… so cheap. We keep itching to buy that stock. We kept getting frozen. You've got a good one." Allergan ( AGN ) : "I'd rather buy Allergan all the way down. That has a good aesthetic business. It is a better play." Bearish Calls: EZchip …
-
Allergan : Is It Still Overvalued?
By Derastone : Allergan 's ( AGN ) 1Q13 earnings of $0.89/share fell short of market expectations ..... that explains the problems with both drugs. Regarding DARPin, Allergan has completed the initial analysis for the second stage of the randomized …
-
Regeneron's Sales and Earnings Rocket in 1Q
… billion-$1.325 billion range. However, we've raised our fair value estimate following the news this week that Allergan 's AGN rival anti-VEGF drug, which could offer improved dosing to Eylea, has encountered troubles in clinical testing …
-
Cramer's Mad Money - The Most Important Game Changer For 2013 (5/2/13)
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday May 2. The Most Important Game Changer For 2013: Eaton ( ETN ), PPG Industries ( PPG ), Avnet ( AVT ), Royal Bank of Scotland ( RBS ), Oil States International ( OIS ), General ...
-
Allergan , Inc . ( AGN ) declares $0.05/share quarterly dividend, in line with previous. Forward yield 0.20%. For shareholders of record May 23. Payable June 13. Ex-div date May 21. (PR)
Allergan , Inc . ( AGN ) declares $0.05/share quarterly dividend, in line with previous. Forward yield 0.20%. For shareholders of record May 23. Payable June 13. Ex-div date May 21. ( PR ) Post your comment!
-
Cramer's Mad Money - Pharmas Live Or Die By The Pipeline (5/1/13)
… Johnson & Johnson ( JNJ ), GlaxoSmithKline ( GSK ), Allergan ( AGN ), Merck ( MRK ), Eli Lilly ( LLY ) The Pharmaceutical ..... wait. Stocks can get crushed by the pipeline, too. Allergan ( AGN ) fell 13% in one day because results were not as …
-
UPDATE 3- Allergan delays drug that would rival Regeneron's Eylea
May 1 (Reuters) - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.
-
Allergan Management Discusses Q1 2013 Results - Earnings Call Transcript
Allergan ( AGN ) Q1 2013 Earnings Call May 01, 2013 11:00 am ET Executives James M ..... br/><a href='http://seekingalpha.com/article/1390801- allergan -management-discusses-q1-2013-results-earnings-call-transcript …
-
Midday top 10 gainers: [[IQNT]] +60%. [[BCOV]] +31%. [[CNIT]] +28%. [[MNOV]] +21%. [[MSPD]] +19%. [[SONS]] +15%. [[TRLA]] +15%. [[RATE]] +15%. [[REGN]] +14%. [[SGI]] +14%. Midday top 10 losers: ...
… 15% . TRLA +15% . RATE +15% . REGN +14% . SGI +14% . Midday top 10 losers: ACCL -21% . RBC -20% . ESBF -17% . LEDS -16% . KFRC -15% . AGN -14% . CRAY -13% . ASTX -13% . XXIA -13% . UTI -12% . Post your comment!
-
Allergan ([[ AGN ]] -9.4%) dives as management - on today's earnings call - has less than great progress to report on a couple of drugs in development. Regeneron ([[REGN]] +12.4%) spikes higher.
Allergan ( AGN -9.4% ) dives as management - on today's earnings call - has less than great progress to report on a couple of drugs in development. Regeneron ( REGN +12.4% ) spikes higher. Post your comment!